The Technical AnalystExchange: HKSE Sector: Pharmaceuticals Industry: Drug Manufacturers—Specialty & Generic
Hua Medicine Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.86% HKD1.580
America/New_York / 3 mai 2024 @ 03:33
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 546.38 mill |
| EPS: | -0.240 |
| P/E: | -6.58 |
| Earnings Date: | Mar 28, 2024 |
| SharesOutstanding: | 978.72 mill |
| Avg Daily Volume: | 1.047 mill |
| RATING 2024-05-02 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | n/a | n/a | n/a | |||
| Asset | n/a | n/a | n/a | |||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -6.58 | sector: PE 23.82 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.50x |
| Company: PE -6.58 | industry: PE 13.09 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
HKD1.116 (-29.39%) HKD-0.464 |
| Date: 2024-05-03 |
| Expected Trading Range (DAY) |
|---|
|
HKD 1.473 - 1.687 ( +/- 6.77%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | HKD1.580 (-1.86% ) |
| Volume | 0.288 mill |
| Avg. Vol. | 1.047 mill |
| % of Avg. Vol | 27.50 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 2552.HK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
2552.HK
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.